KYOTO,
Japan, May 17, 2024 /PRNewswire/ -- OMRON
Healthcare Co., Ltd. based in Muko, Kyoto
Prefecture, Japan,
announced its presence at Heart Rhythm 2024, the Annual Meeting of
the Heart Rhythm Society (HRS) in the U.S. At Heart Rhythm 2024,
the Company will showcase its upper-arm blood pressure monitor with
ECG technology, Complete, and a series of home-use blood pressure
monitors. In addition, OMRON will support a CME (Continuing Medical
Education)-accredited breakfast symposium (*1) discussing early
detection of atrial fibrillation (AFib) and the management of
hypertensive patients. The result of a clinical trial utilizing new
technology to detect the AFib using OMRON blood pressure monitors
will be also presented at the symposium.
Logo:
https://kyodonewsprwire.jp/img/202405130656-O1-b0U0s3Y5
Heart Rhythm 2024 is organized by the Heart Rhythm Society (HRS)
and provides a platform to advance the field of
electrophysiology (EP) and improve patient outcomes through the
exchange of groundbreaking science, cutting-edge technologies, and
life-saving therapies. At the CME Breakfast Symposium at Heart
Rhythm 2024, Dr. Vivek Reddy,
Director of Cardiac Arrhythmia Services at the Mount Sinai Hospital
and the Mount Sinai Health System, will moderate it under the theme
of and discuss AFib detection among hypertensive patients and the
clinical significance of the early detection of AFib by using
cutting-edge technology with other prominent experts.
(*1) This program is not part of the Heart Rhythm 2024 Official
Scientific Sessions as planned by the Heart Rhythm Society
Scientific Sessions Program Committee. The event is neither
sponsored nor endorsed by the Heart Rhythm Society.
"Going for Zero" is the vision of OMRON's cardiovascular domain:
Reducing the incidence of cerebrovascular and cardiovascular
diseases to zero and one of its goals is to provide a solution for
the early detection of AFib. Early AFib detection can help prevent
serious complications such as heart attack or stroke. However, the
challenge is that about 40% of patients are asymptomatic, making
early detection difficult. Study shows that hypertensive patients
develop AFib three times higher than individuals with a normal
range of blood pressure (*2). Since 2019, the Company has been
expanding devices and services globally including upper arm blood
pressure monitors with built-in ECG technology and a home-use
portable ECG that quickly detects the possibility of AFib. The
Company actively participates in academic conference activities and
clinical studies held in various countries around the world and has
been working on advancing the early detection technology of AFib in
collaboration with healthcare professionals and researchers. The
Company will continue to promote academic activities globally,
develop devices and services, and contribute to empowering people
worldwide to live life to the fullest.
(*2) Senoo K, Yukawa A, Ohkura T, et al., Screening for
untreated atrial fibrillation in the elderly population: A
community-based study. Pizzi C, ed. PLoS ONE.
2022;17(6):e0269506.
Symposium Overview
Date: Saturday, May 18, 2024
Location: Boston Convention and Exhibition Center, Room:
205ABC
Agenda:
5:30 - 6:10 AM Check-In and Breakfast
Buffet
6:10 - 6:15 AM Welcome and
Introductions/ Vivek Reddy, MD
6:15 - 6:30 AM AF and Hypertension:
Dangerous Bedfellows/ Ben Freedman,
MBBS, PhD
6:30 - 6:45 AM Advanced AI in a Blood
Pressure Monitor to Enhance AF Detection at Home/ Matt Janik, MD, FACC
6:45 - 7:00 AM AF Screening in
Patients with Hypertension: A Nationwide Decentralized
Clinical Trial/ Keitaro Senoo,
MD
7:00 - 7:30 AM Panel Discussion with
Q&A Session
U.S.: https://omronhealthcare.com/
International: https://healthcare.omron.com/
Japan:
https://www.healthcare.omron.co.jp/
View original
content:https://www.prnewswire.com/news-releases/omron-healthcares-presence-at-heart-rhythm-2024-in-the-us-302148598.html
SOURCE OMRON Healthcare Co., Ltd.